Rose Capital Advisors’s AbbVie ABBV Stock Holding History

Rose Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$266K	Buy	+1,056	New	+$227K	0.13%	90

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Rose Capital Advisors's ABBV Position: Q2 2026 in Review

Rose Capital Advisors opened a new position in AbbVie (ABBV) in Q2 2026: 1,056 shares worth $266K. The stake represents 0.13% of the portfolio and ranks #90 among its holdings.

4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Rose Capital Advisors held 1,056 shares of AbbVie worth $266K as of Q2 2026.
AbbVie was a new Rose Capital Advisors position in Q2 2026.
AbbVie made up 0.13% of Rose Capital Advisors's portfolio in Q2 2026, its #90 holding.
4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Rose Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.